The 9 analysts offering 12-month price forecasts for Enanta Pharmaceuticals Inc have a median target of 60.00, with a high estimate of 117.00 and a low estimate of 30.00. The median estimate represents a +28.29% increase from the last price of 46.77.
The current consensus among 9 polled investment analysts is to Buy stock in Enanta Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.79
Reporting Date Feb 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.